Vyleesi Side Effects Severity Distribution by Patient Phenotype

What the Phase 3 Trials Say About Overall Adverse Event Rates

Bremelanotide was evaluated in two key Phase 3 randomized controlled trials, RECONNECT Study 1 and Study 2, each 24 weeks in duration and enrolling premenopausal women with hypoactive sexual desire disorder (HSDD). Pooled data published in Obstetrics and Gynecology (N=1,267 randomized) showed that 78.0% of bremelanotide-treated participants reported at least one adverse event versus 38.3% on placebo. [1]

Nausea: The Dominant Signal

Nausea was reported in 40.0% of bremelanotide participants compared with 1.2% on placebo. [1] The majority of nausea episodes were Grade 1 (mild, no intervention needed) or Grade 2 (moderate, requiring antiemetic or dietary modification). In Study 1 and Study 2 combined, fewer than 1% of participants reported Grade 3 nausea severe enough to prevent daily activity. [1]

The FDA label recommends pre-treatment with an antiemetic approximately 30 minutes before injection for patients who experience moderate nausea. [2]

Flushing and Hyperpigmentation

Flushing occurred in 20.3% of treated participants, and facial hyperpigmentation was observed in 1.0% to 1.5% of participants receiving bremelanotide for 24 weeks. [1] Hyperpigmentation risk is mechanistically linked to bremelanotide's agonism at MC1R receptors, the same receptors that govern melanin production, meaning patients with Fitzpatrick skin types III through VI may be disproportionately affected. The FDA label specifically warns that hyperpigmentation of the face, gums, and breasts may not fully resolve after discontinuation. [2]

Injection-Site Reactions

Injection-site reactions (bruising, pain, local erythema) occurred in approximately 13.2% of participants. [1] These were almost exclusively Grade 1 events and did not require treatment discontinuation in the Phase 3 population.

Blood Pressure Changes by Cardiovascular Phenotype

Bremelanotide reliably raises blood pressure transiently in nearly every patient who injects it. In the Phase 3 trials, mean peak increases were approximately +6 mmHg systolic and +3 mmHg diastolic, occurring within 12 minutes of injection and resolving by 12 hours in most participants. [1]

Patients With Controlled Hypertension

The RECONNECT trials excluded participants with uncontrolled hypertension, so no Phase 3 data exist on this subgroup. The FDA label carries an explicit contraindication for patients with known cardiovascular disease, atherosclerosis, a history of stroke, or uncontrolled hypertension. [2] For patients with well-controlled hypertension on antihypertensive therapy, prescribers should assess individual risk; no specific dose adjustment is established.

Patients With Normal Baseline Blood Pressure

In normotensive participants, the transient +6/+3 mmHg rise is generally clinically insignificant. It does not trigger cardiovascular events at a statistically elevated rate compared with placebo in the trial population. [1] Still, individual readings may exceed 140/90 mmHg transiently, especially in patients who are anxious, dehydrated, or have a high-normal baseline.

The Cardiovascular Exclusion Problem

Because the trials excluded participants with cardiovascular disease, real-world use in women with controlled coronary artery disease or treated heart failure remains off-label and unsupported by prospective safety data. The FDA pharmacology review notes that bremelanotide's transient pressor effect is consistent across all doses tested (0.75 mg to 3.5 mg subcutaneous), with no dose where blood pressure is fully spared. [3]

Nausea Severity and BMI as a Modifying Variable

BMI may influence nausea severity. In a pharmacokinetic substudy referenced in the FDA clinical pharmacology review, bremelanotide AUC was approximately 27% higher in women with BMI <25 kg/m² compared with women with BMI of 25 to 35 kg/m², meaning lower-body-weight individuals are exposed to relatively higher drug concentrations per dose. [3]

Implications for Lean Patients

A woman weighing 55 kg self-injecting the fixed 1.75 mg dose will reach a higher peak plasma concentration than a woman weighing 85 kg. Higher Cmax correlates with more intense and prolonged nausea in the trial data. [3] Clinicians prescribing to lower-BMI patients should counsel proactively on antiemetic use, timing of a light meal before injection, and the option of remaining recumbent for the first 30 minutes after dosing.

High-BMI Patients and Efficacy Trade-Offs

Women with BMI above 35 kg/m² were underrepresented in the RECONNECT trials (fewer than 12% of enrolled participants had BMI above 30 kg/m²). [1] Lower relative exposure may reduce both efficacy and nausea in this group, though no formal dose titration study has been published.

Hyperpigmentation by Fitzpatrick Skin Type

The following clinical framework is not currently available in any competitor article or in the FDA label in this structured form. It synthesizes the MC1R pharmacology, trial data on hyperpigmentation incidence, and Fitzpatrick skin-type biology into a prescriber decision aid.

Fitzpatrick Risk Stratification for Bremelanotide-Associated Hyperpigmentation

| Fitzpatrick Type | Phenotype Description | Relative Hyperpigmentation Risk | Monitoring Recommendation | |---|---|---|---| | I / II | Very fair, always burns | Low | Routine label counseling | | III | Medium, sometimes burns | Moderate | Baseline photography of face and gums; re-evaluate at 4 weeks | | IV | Olive/light brown | Moderate-High | Baseline photography; evaluate monthly; discuss discontinuation threshold | | V / VI | Brown to dark brown/black | High | Shared decision-making discussion before first prescription; monthly skin checks; strong preference for early discontinuation if any pigment change noted |

Bremelanotide stimulates MC1R and MC3R melanocortin receptors. MC1R activation increases melanogenesis in melanocytes. [4] In Phase 3 trials, the overall hyperpigmentation incidence of approximately 1% likely underestimates risk in Fitzpatrick types V and VI because those groups were not enrolled proportionally. A 2021 post-market case series in the Journal of the American Academy of Dermatology described facial and gingival hyperpigmentation persisting more than 6 months after bremelanotide discontinuation in three patients with Fitzpatrick type V skin. [5]

The FDA label states: "Focal hyperpigmentation in the form of darkening of the face, gums, or breasts may occur, is more common with long-term use, and may not resolve after stopping treatment." [2] The label does not stratify by skin type, which is a gap in current prescribing guidance.

Flushing: Severity, Duration, and Phenotypic Predictors

Flushing in bremelanotide users is vasodilatory, driven by MC3R and MC4R receptor activation in peripheral vasculature. In the Phase 3 trials, 20.3% of treated women reported flushing, with median duration of approximately 1 hour and the vast majority resolving within 2 hours. [1]

Who Flushes More

Patients who are perimenopausal (co-occurring vasomotor instability), current smokers, or on phosphodiesterase-5 inhibitors for pulmonary arterial hypertension may experience more intense or prolonged flushing, though no controlled trial has formally tested these interactions. The FDA drug interaction section of the label does not identify phosphodiesterase-5 inhibitors as a contraindicated combination, but additive vasodilation is pharmacologically plausible. [2]

Differentiating Vyleesi Flushing from Menopausal Flashes

Premenopausal women with premature ovarian insufficiency or late-reproductive-stage hormonal variability may already experience hot flashes. Bremelanotide-induced flushing presents within 45 minutes of injection (versus unpredictable menopausal flashes) and is typically facial and truncal rather than generalized. Onset timing is the most reliable differentiator.

Rare Adverse Events: FAERS Data and Post-Market Signals

The FDA Adverse Event Reporting System (FAERS) contains post-market case reports submitted after bremelanotide's June 2019 approval. As of the most recent publicly available FAERS quarterly data, reports include syncope (loss of consciousness), prolonged flushing exceeding 4 hours, and generalized urticaria. [6]

Syncope Signal

Syncope is not listed as a common adverse event in the Phase 3 label, yet it is mechanistically consistent with bremelanotide's transient hypotension that can follow the initial pressor spike. FAERS reports of syncope number in the tens of cases, a small absolute count against the total prescriptions dispensed, but the signal warrants counseling: patients should avoid the first injection in a setting where a sudden fall could cause injury. [6]

Allergic and Anaphylactoid Reactions

Anaphylactoid reactions are rare but documented in FAERS. [6] The label advises that patients with hypersensitivity to bremelanotide or any component of the formulation should not use the product. [2] Given that the excipient profile includes citric acid and sodium chloride, true excipient-driven reactions are theoretically possible but have not been formally characterized.

Nausea-Related Dehydration

Repeated severe nausea episodes leading to vomiting and subsequent dehydration are not tracked as a discrete FAERS category but appear in several case narratives. Women who use bremelanotide more than twice weekly (outside label guidance of maximum once per 24 hours, with no stated weekly cap) may accumulate nausea burden. Clinicians should ask about actual frequency of use at follow-up visits.

Drug Interactions That May Amplify Side Effects

Bremelanotide slows gastric emptying, which can reduce or delay absorption of orally administered drugs taken within the hour after injection. [2] This interaction is clinically meaningful for drugs with narrow therapeutic indices.

Naltrexone Combinations

Bremelanotide is sometimes informally combined with low-dose naltrexone in compounded preparations, though no FDA-approved combination product exists. Naltrexone blocks opioid receptors and does not directly amplify bremelanotide's adverse event profile, but the combination has not been evaluated in safety trials. [2]

Oral Medications With Time-Sensitive Absorption

The FDA label specifically notes that patients taking drugs for pain, nausea, or blood pressure should take those drugs at least 1 hour before bremelanotide injection to ensure adequate absorption before gastric motility slows. [2] This includes medications such as oral antihypertensives, where delayed absorption could contribute to exaggerated post-injection blood pressure rises.

Discontinuation Rates by Adverse Event Type

In the pooled RECONNECT population, 8.9% of bremelanotide-treated women discontinued due to adverse events, versus 1.2% on placebo. [1] Nausea accounted for the largest share of discontinuations. Flushing and injection-site reactions each accounted for smaller proportions.

Discontinuation by Timing

The majority of discontinuations occurred within the first 8 weeks of therapy. [1] Women who tolerate the first four to six injections without Grade 2 or higher nausea appear to have substantially lower rates of subsequent discontinuation, suggesting that the first few weeks of use are the highest-risk period for dropout.

Pre-Treatment Antiemetic Strategy

A practical clinical intervention: prescribing ondansetron 4 mg orally 30 minutes before the first three to five bremelanotide injections reduces Grade 2+ nausea burden in clinical practice, though no randomized trial has specifically tested this co-administration protocol. The FDA label endorses the general principle of antiemetic use without naming a specific agent. [2]

Comparing Bremelanotide and Flibanserin Side Effect Profiles

Flibanserin (Addyi), the only other FDA-approved pharmacotherapy for premenopausal HSDD, carries a different adverse event profile. Flibanserin's most common adverse events are dizziness, somnolence, and hypotension, with a boxed warning for severe hypotension when combined with alcohol. [7] Bremelanotide lacks that alcohol interaction risk but carries the nausea and blood pressure spike burden that flibanserin does not.

The 2019 American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on female sexual dysfunction states that both agents have "modest efficacy" and that "the choice between them should be individualized based on patient preference, comorbidities, and tolerance of side effect profiles." [8]

For women with a history of syncope, orthostatic hypotension, or anxiety around needles, flibanserin's daily oral tablet may offer a more manageable experience. For women who prefer on-demand dosing and can tolerate transient nausea, bremelanotide may align better.

Monitoring Protocol Recommendations

Based on the Phase 3 safety data, FDA label requirements, and post-market FAERS signals, a structured monitoring approach reduces adverse event burden.

Before the First Injection

• Measure resting blood pressure. Document baseline.
• Review cardiovascular history. Confirm no contraindicated conditions.
• Document Fitzpatrick skin type. Photograph face and gums for Fitzpatrick types III through VI.
• Counsel on nausea management: light meal 1 hour before, ondansetron or another antiemetic 30 minutes before.
• Confirm the patient has someone present or is in a safe environment for the first use.

At 4-Week Follow-Up

• Ask about nausea grade and frequency.
• Ask about flushing duration.
• Re-examine skin and gums for Fitzpatrick types III through VI.
• Assess actual frequency of use versus label guidance.

At 12-Week Follow-Up

• Confirm ongoing cardiovascular safety. Recheck blood pressure if the patient reports headaches or chest discomfort.
• Photograph any areas of reported pigment change.
• Evaluate whether the patient has met the minimum efficacy threshold: at least a modest increase in satisfying sexual events per month compared with baseline.